TIL Technology

In the early stages of cancer, special immune cells known as tumor infiltrating lymphocytes (TILs) migrate to the tumor and launch an attack. However, this effect is usually short-lived because cancer adapts to evade immune detection and suppress immune response. Lion's TIL technology is designed to overcome the immunosuppressive effects of cancer, while leveraging and enhancing the power of TILs to treat, and potentially cure, all solid tumors.

TIL technology has demonstrated robust efficacy in Phase 2 clinical trials, indicating objective response rates of 56% in metastatic melanoma. Based on an adoptive cell therapy regimen developed by Steven A. Rosenberg, MD, chief of surgery at National Cancer Institute (NCI), it is currently in use as a physician-sponsored investigational treatment for metastatic melanoma at NCI, MD Anderson Cancer Center, and the H. Lee Moffitt Cancer & Research Institute.

Cancer suppresses and evades immune system
Our Solution: TIL Technology
Enables and enhances robust immune response
Tumor heterogeneity - Cancer consists of many different cell types that can mutate hundreds of times over, allowing them to evade immune detection Targeting patient-specific antigens - Unlike many cancer vaccines which target preselected tumor antigens, our technology is based on a patient's own TILs, which naturally target antigens specific to that patient's tumor
Insufficient T-cell response - Tumor micro-environment deactivates T-cells and inhibits their growth, so they are insufficient in number and potency to mount an adequate immune response Enhancing T-cell number and potency - TILs isolated from a resected tumor are expanded to several billion cells in vitro, away from suppressive influences, enabling administration of potent, highly activated cells
Immune suppression - Proteins on the surface of tumor cells, such as PD-1 and CTLA4, inhibit T-cell response Controlling tumor micro-environment to reduce immune suppression - Patient is preconditioned to remove all suppressive influences prior to infusion of cultured TILs to enhance therapeutic outcome

How It Works

Our technology is based on TILs isolated from the patient's tumor following resection. The cells are then expanded to billions in vitro, away from cancer's immune-suppressing effects. These highly activated, potent TILs are then infused back into the patient, who has been preconditioned to remove all suppressive influences.